non-Hodgkin lymphoma Archives -

Japan’s Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor

Daiichi Sankyo grabs first approval for blood cancer drug Ezharmia

https://pharmaphorum.com/news/daiichi-sankyo-grabs-first-approval-for-blood-cancer-drug-ezharmia/

Market Access/ News/ News/ News/ Oncology

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Phil Taylor BeiGene, Brukinsa, HEOR, NICE, non-Hodgkin lymphoma, Oncology, UK 0 Comment

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine

NICE says yes to BeiGene’s Brukinsa after Scottish nay

https://pharmaphorum.com/news/nice-says-yes-to-beigenes-brukinsa-after-scottish-nay/

News/ News/ Oncology

Troubled Nordic Nanovector “exploring strategic options”

Phil Taylor Betalutin, follicular lymphoma, non-Hodgkin lymphoma, Nordic Nanovector, Oncology, radionuclide 0 Comment

Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started

Troubled Nordic Nanovector “exploring strategic options”

https://pharmaphorum.com/news/troubled-nordic-nanovector-exploring-strategic-options/

News/ News/ News/ Oncology/ Sales and Marketing

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

Phil Taylor antibody-drug conjugate, diffuse B-Cell lymphoma, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, regulatory, Roche 0 Comment

The FDA has started a review of Roche’s Polivy for people with previously untreated diffuse large B-cell lymphoma

Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy

https://pharmaphorum.com/news/roche-eyes-april-fda-verdict-on-polivy-as-first-line-lymphoma-therapy/

News/ News/ News/ Oncology/ Sales and Marketing

Sobi bolsters blood division via $435m ADC licensing deal

Phil Taylor ADC Therapeutics, licensing, loncastuximab tesirine, non-Hodgkin lymphoma, Oncology, SOBI, Zynlonta 0 Comment

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy

Sobi bolsters blood division via $435m ADC licensing deal

https://pharmaphorum.com/news/sobi-bolsters-blood-division-via-435m-adc-licensing-deal/

Market Access/ News/ News/ News/ Oncology

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

Phil Taylor follicular lymphoma, immuno-oncology, Lunsumio, non-Hodgkin lymphoma, Oncology, Roche 0 Comment

The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

https://pharmaphorum.com/news/fda-to-decide-on-roches-lymphoma-drug-lunsumio-before-year-end/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ News/ Oncology/ R&D

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo

Phil Taylor Amgen, AstraZeneca, Blincyto, Gilead Sciences, immuno-oncology, M&A, non-Hodgkin lymphoma, Oncology, Tecartus, TeneoTwo 0 Comment

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo

https://pharmaphorum.com/news/astrazeneca-agrees-1-3bn-deal-to-buy-oncology-player-teneotwo/

Market Access/ News/ News/ News/ Oncology

EU first to clear Roche’s lymphoma bispecific mosunetuzumab

Phil Taylor follicular lymphoma, immuno-oncology, Lunsumio, mosunetuzumab, non-Hodgkin lymphoma, Oncology, regulatory approval, Roche 0 Comment

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for

EU first to clear Roche’s lymphoma bispecific mosunetuzumab

https://pharmaphorum.com/news/eu-first-to-clear-roches-lymphoma-bispecific-mosunetuzumab/

News/ News/ Oncology

Roche trumpets new glofitamab data in lymphoma at ASCO

Phil Taylor bispecific antibody, diffuse B-Cell lymphoma, epcoritamab, glofitamab, non-Hodgkin lymphoma, Polivy, Roche 0 Comment

Roche will present the new data at next week’s ASCO congress showing that its bispecific antibody glofitamab can

Roche trumpets new glofitamab data in lymphoma at ASCO

https://pharmaphorum.com/news/roche-trumpets-new-glofitamab-data-in-lymphoma-at-asco/

Trending

non-Hodgkin lymphoma

Login